Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

Compare

951 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

APLS Analyst Ratings

Moderate Buy

10 Buy

8 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Apellis

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

APLS Stock 12 Month Forecast

Average Price Target

$36.53

▲(50.95% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Apellis Pharmaceuticals in the last 3 months. The average price target is $36.53 with a high forecast of $60.00 and a low forecast of $19.00. The average price target represents a 50.95% change from the last price of $24.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","61":"$61","27.25":"$27.3","38.5":"$38.5","49.75":"$49.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,27.25,38.5,49.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.95,25.799999999999997,28.65,31.5,34.349999999999994,37.199999999999996,40.05,42.89999999999999,45.75,48.599999999999994,51.449999999999996,54.3,57.14999999999999,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.95,23.994615384615383,25.03923076923077,26.083846153846153,27.128461538461536,28.173076923076923,29.217692307692307,30.262307692307694,31.306923076923077,32.35153846153846,33.39615384615385,34.440769230769234,35.48538461538462,{"y":36.53,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.95,22.646153846153844,22.342307692307692,22.038461538461537,21.734615384615385,21.43076923076923,21.126923076923077,20.823076923076922,20.51923076923077,20.215384615384615,19.911538461538463,19.607692307692307,19.303846153846155,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.9,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.91,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.87,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$36.53

Lowest Price Target$19.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$24

Hold

-0.83%

Downside

Reiterated

08/02/25

Apellis Pharmaceuticals' overall score is driven by strong technical momentum and promising developments in its product pipeline, particularly EMPAVELI. However, profitability challenges and valuation concerns weigh on the score. The company's strategic initiatives, including the royalty buy-down deal, provide a positive outlook for financial stability and future growth.

Graig SuvannavejhMizuho Securities

Mizuho Securities

$21→$22

Hold

-9.09%

Downside

Reiterated

08/04/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (NASDAQ: APLS) and Akero Therapeutics (NASDAQ: AKRO)Following APLS' 2Q results, we now raise our PT to $22 (vs. $21, prior) and we stay Neutral on APLS.

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$83→$57

Buy

135.54%

Upside

Reiterated

08/01/25

Apellis Pharmaceuticals: Buy Rating Driven by Empaveli's Market Potential and Strong Growth Prospects

Ryan DeschnerRaymond James

Raymond James

$52→$50

Buy

106.61%

Upside

Reiterated

08/01/25

Apellis price target lowered to $50 from $52 at Raymond JamesApellis price target lowered to $50 from $52 at Raymond James

Anupam RamaJ.P. Morgan

J.P. Morgan

$35→$37

Buy

52.89%

Upside

Reiterated

08/01/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (NASDAQ: APLS) and Illumina (NASDAQ: ILMN)We are establishing a December 2026 price target on APLS shares of $37 (prior December 2025 PT of $35).

Steven SeedhouseCantor Fitzgerald

Cantor Fitzgerald

$39.2→$40

Buy

65.29%

Upside

Reiterated

07/31/25

Apellis Pharmaceuticals (APLS) Receives a Buy from Cantor Fitzgerald

Salveen RichterGoldman Sachs

Goldman Sachs

$24→$26

Hold

7.44%

Upside

Reiterated

07/31/25

Apellis price target raised to $26 from $24 at Goldman SachsApellis price target raised to $26 from $24 at Goldman Sachs

Phil NadeauTD Cowen

TD Cowen

$50

Buy

106.61%

Upside

Reiterated

07/31/25

Apellis Pharmaceuticals (APLS) Receives a Buy from TD CowenWe continue to believe that APLS is undervalued. RemainBuy.

Tazeen AhmadBank of America Securities

Bank of America Securities

$25→$26

Hold

7.44%

Upside

Reiterated

07/31/25

Steady Growth and Future Potential: A Hold Rating for Apellis Pharmaceuticals

Lisa WalterRBC Capital

RBC Capital

$17→$19

Hold

-21.49%

Downside

Reiterated

07/31/25

RBC Capital Sticks to Their Hold Rating for Apellis Pharmaceuticals (APLS)

Judah FrommerMorgan Stanley

Morgan Stanley

$26

Hold

7.44%

Upside

Reiterated

07/31/25

Cautious Outlook on Apellis Pharmaceuticals: Hold Rating Amidst Modest Syfovre Growth and Empaveli ExpansionWe will remain interested in indications of overall GA market growth, but can now look toward early signs of launch contribution from an expanded Empaveli label as well as we head into late 2025.

Greg HarrisonScotiabank

Scotiabank

$20→$22

Hold

-9.09%

Downside

Reiterated

07/30/25

Apellis Pharmaceuticals (APLS) Receives a Hold from Scotiabank

Joseph StringerNeedham

Needham

$29

Buy

19.83%

Upside

Reiterated

07/29/25

Buy Rating for Apellis Pharmaceuticals Driven by FDA Approval and Promising Financial Projections for Empaveli

Yigal NochomovitzCiti

Citi

$41→$52

Buy

114.88%

Upside

Reiterated

07/29/25

Apellis price target raised to $46 from $41 at CitiApellis price target raised to $46 from $41 at Citi

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

$60

Buy

147.93%

Upside

Reiterated

07/29/25

Stifel Nicolaus Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$24

Hold

-0.83%

Downside

Reiterated

08/02/25

Graig SuvannavejhMizuho Securities

Mizuho Securities

$21→$22

Hold

-9.09%

Downside

Reiterated

08/04/25

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$83→$57

Buy

135.54%

Upside

Reiterated

08/01/25

Apellis Pharmaceuticals: Buy Rating Driven by Empaveli's Market Potential and Strong Growth Prospects

Ryan DeschnerRaymond James

Raymond James

$52→$50

Buy

106.61%

Upside

Reiterated

08/01/25

Apellis price target lowered to $50 from $52 at Raymond JamesApellis price target lowered to $50 from $52 at Raymond James

Anupam RamaJ.P. Morgan

J.P. Morgan

$35→$37

Buy

52.89%

Upside

Reiterated

08/01/25

Steven SeedhouseCantor Fitzgerald

Cantor Fitzgerald

$39.2→$40

Buy

65.29%

Upside

Reiterated

07/31/25

Apellis Pharmaceuticals (APLS) Receives a Buy from Cantor Fitzgerald

Salveen RichterGoldman Sachs

Goldman Sachs

$24→$26

Hold

7.44%

Upside

Reiterated

07/31/25

Apellis price target raised to $26 from $24 at Goldman SachsApellis price target raised to $26 from $24 at Goldman Sachs

Phil NadeauTD Cowen

TD Cowen

$50

Buy

106.61%

Upside

Reiterated

07/31/25

Apellis Pharmaceuticals (APLS) Receives a Buy from TD CowenWe continue to believe that APLS is undervalued. RemainBuy.

Tazeen AhmadBank of America Securities

Bank of America Securities

$25→$26

Hold

7.44%

Upside

Reiterated

07/31/25

Steady Growth and Future Potential: A Hold Rating for Apellis Pharmaceuticals

Lisa WalterRBC Capital

RBC Capital

$17→$19

Hold

-21.49%

Downside

Reiterated

07/31/25

RBC Capital Sticks to Their Hold Rating for Apellis Pharmaceuticals (APLS)

Judah FrommerMorgan Stanley

Morgan Stanley

$26

Hold

7.44%

Upside

Reiterated

07/31/25

Greg HarrisonScotiabank

Scotiabank

$20→$22

Hold

-9.09%

Downside

Reiterated

07/30/25

Apellis Pharmaceuticals (APLS) Receives a Hold from Scotiabank

Joseph StringerNeedham

Needham

$29

Buy

19.83%

Upside

Reiterated

07/29/25

Buy Rating for Apellis Pharmaceuticals Driven by FDA Approval and Promising Financial Projections for Empaveli

Yigal NochomovitzCiti

Citi

$41→$52

Buy

114.88%

Upside

Reiterated

07/29/25

Apellis price target raised to $46 from $41 at CitiApellis price target raised to $46 from $41 at Citi

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

$60

Buy

147.93%

Upside

Reiterated

07/29/25

Stifel Nicolaus Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Apellis Pharmaceuticals

1 Month

xxx

Success Rate

19/29 ratings generated profit

Average Return

+4.96%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.52% of your transactions generating a profit, with an average return of +4.96% per trade.

3 Months

xxx

Success Rate

18/28 ratings generated profit

Average Return

+5.34%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +5.34% per trade.

1 Year

Yigal NochomovitzCiti

Success Rate

14/30 ratings generated profit

Average Return

+4.54%

reiterated a buy rating 11 days ago

Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +4.54% per trade.

2 Years

xxx

Success Rate

15/28 ratings generated profit

Average Return

+2.67%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 53.57% of your transactions generating a profit, with an average return of +2.67% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

APLS Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, APLS has received 18 Buy Ratings, 26 Hold Ratings, and 0 Sell Ratings. APLS average Analyst price target in the past 3 months is 36.53.

Each month's total comprises the sum of three months' worth of ratings.

APLS Financial Forecast

APLS Earnings Forecast

Next quarter’s earnings estimate for APLS is $1.60 with a range of $1.04 to $2.03. The previous quarter’s EPS was -$0.33. APLS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year APLS has Preformed in-line its overall industry.

APLS Sales Forecast

Next quarter’s sales forecast for APLS is $371.55M with a range of $175.34M to $504.68M. The previous quarter’s sales results were $178.49M. APLS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year APLS has Preformed in-line its overall industry.

APLS Stock Forecast FAQ

What is APLS’s average 12-month price target, according to analysts?

Based on analyst ratings, Apellis Pharmaceuticals’s 12-month average price target is 36.53.

What is APLS’s upside potential, based on the analysts’ average price target?

Apellis Pharmaceuticals has 50.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is APLS a Buy, Sell or Hold?

Apellis Pharmaceuticals has a consensus rating of Moderate Buy which is based on 10 buy ratings, 8 hold ratings and 0 sell ratings.

What is Apellis Pharmaceuticals’s price target?

The average price target for Apellis Pharmaceuticals is 36.53. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $19.00. The average price target represents 50.95% Increase from the current price of $24.2.

What do analysts say about Apellis Pharmaceuticals?

Apellis Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of APLS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

APLS Analyst Ratings

APLS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Apellis Pharmaceuticals

APLS Analyst Recommendation Trends

APLS Financial Forecast

APLS Earnings Forecast

APLS Sales Forecast

APLS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts